id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2136-0004,FDA,FDA-2022-E-2136,Determination of Regulatory Review Period for Purposes of Patent Extension; Truseltiq,Notice,Determinations,2023-12-07T05:00:00Z,2023,12,2023-12-07T05:00:00Z,2024-02-06T04:59:59Z,2023-12-07T15:08:31Z,2023-26885,0,0,090000648630ab6a
FDA-2022-E-2136-0003,FDA,FDA-2022-E-2136,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-01-18T05:00:00Z,2023,1,2023-01-18T05:00:00Z,,2023-01-18T20:54:16Z,,0,0,09000064855f6c3d